证券代码：603297 证券简称：永新光学 公告编号：2024-021 宁波永新光学股份有限公司 关于回购注销部分限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1、2023 年 7 月 4 日及 2023 年 7 月 21 日，公司分别召开第七届董事会第二 十次会议、第七届监事会第二十次会议及 2023 年第一次临时股东大会，审议通 过了《关于<公司 2023 年限制性股票激励计划（草案）>及其摘要的议案》《关 于<公司 2023 年限制性股票激励计划实施考核管理办法>的议案》以及《关于提 请股东大会授权董事会办理公司股权激励计划相关事项的议案》。公司就内幕信 息知情人在本次激励计划草案公告前 6 个月内买卖公司股票的情况进行了自查， 未发现存在利用内幕信息进行股票交易的情形，并于 2023 年 7 月 22 日披露了 《关于 2023 年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情 况的自查报告》（公告编号：2023-041）。 2、2023 年 7 月 28 日，公司召开第八届董事会第二次会 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 215,915,276.32, representing a year-on-year increase of 14.74%[16] - The net profit attributable to shareholders of the listed company was CNY 45,559,746.67, a decrease of 3.85% compared to the same period last year[16] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 39,741,915.45, an increase of 27.09%[16] - The company reported a basic earnings per share of CNY 0.41, down by 4.65% year-on-year[16] - The weighted average return on equity was 2.42%, a decrease of 0.74% compared to the same period last year[16] - Net profit for Q1 2024 was ¥45,478,308.03, slightly down from ¥47,225,436.42 in Q1 2023, indicating a decrease of 3.70%[39] - The total comprehensive income for Q1 2024 is approximately CNY 45.46 million, down from CNY 47.14 million in Q1 2023, indicating a decrease of about 3.56%[40] - The basic and diluted earnings per share for Q1 2024 are both CNY 0.41, compared to CNY 0.43 in Q1 2023, reflecting a decline of approximately 4.65%[40] Cash Flow and Liquidity - The net cash flow from operating activities was CNY -4,860,220.52, reflecting a decrease of 110.76% year-on-year[16] - The net cash flow from operating activities for Q1 2024 is negative CNY 4.86 million, a significant decrease from positive CNY 45.18 million in Q1 2023[42] - Cash inflows from operating activities totaled CNY 221.87 million in Q1 2024, down from CNY 232.41 million in Q1 2023, a decrease of about 4.99%[42] - Cash outflows from operating activities increased to CNY 226.73 million in Q1 2024, compared to CNY 187.22 million in Q1 2023, an increase of approximately 21.06%[42] - The net cash flow from investing activities for Q1 2024 is negative CNY 27.91 million, contrasting with positive CNY 106.35 million in Q1 2023[42] - The company received CNY 600,000 from investment activities in Q1 2024, while it had no cash inflow from this category in Q1 2023[42] - The company reported a foreign exchange impact on cash and cash equivalents of CNY 3.95 million in Q1 2024, compared to CNY 2.35 million in Q1 2023, indicating an increase of approximately 68.00%[42] Assets and Liabilities - Total assets at the end of Q1 2024 amounted to CNY 2,103,338,532.20, a slight increase of 0.53% from the end of the previous year[18] - The total liabilities as of the end of Q1 2024 amounted to ¥240,573,672.07, a decrease from ¥279,740,275.16 at the end of Q1 2023[37] - Shareholders' equity attributable to the listed company was CNY 1,862,166,806.34, up by 2.76% compared to the end of the previous year[18] - The total equity attributable to shareholders reached ¥1,862,166,806.34 in Q1 2024, up from ¥1,812,129,264.19 in Q1 2023, reflecting an increase of 2.76%[37] - The company has no preferred shares or perpetual bonds reported in the liabilities section, indicating a straightforward capital structure[37] Research and Development - Research and development expenses increased to ¥28,547,799.23 in Q1 2024, compared to ¥19,237,182.11 in Q1 2023, marking a significant rise of 48.49%[39] Shareholder Information - The total number of shareholders at the end of the reporting period was 9,104, with significant holdings from major shareholders such as 永新光电实业有限公司 and 宁兴（宁波）资产管理有限公司[33] Cash and Cash Equivalents - The company's cash and cash equivalents decreased to CNY 789,848,748.91 from CNY 818,315,442.28 at the end of the previous year[29] - The cash and cash equivalents at the end of Q1 2024 amount to CNY 789.83 million, compared to CNY 424.52 million at the end of Q1 2023, showing an increase of approximately 86.00%[42]

目 录 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明…………………………………………………………第 1—2 页 二、非经营性资金占用及其他关联资金往来情况汇总表…………… 第 3 页 非经营性资金占用及其他关联资金往来情况的 专项审计说明 第 1 页 共 3 页 三、注册会计师的责任 我们的责任是在实施审计工作的基础上对永新光学公司管理层编制的汇总 表发表专项审计意见。 天健审〔2024〕2993 号 宁波永新光学股份有限公司全体股东： 我们接受委托，审计了宁波永新光学股份有限公司（以下简称永新光学公司） 2023 年度财务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债表，2023 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权 益变动表，以及财务报表附注，并出具了审计报告。在此基础上，我们审计了后 附的永新光学公司管理层编制的 2023 年度《非经营性资金占用及其他关联资金 往来情况汇总表》（以下简称汇总表）。 一、对报告使用者和使用目的的限定 本报告仅供永新光学公司年度报告披露时使用，不得用作任何其他目的。我 们同意将本报告作为永新光学公司年度报告 ...

第八届董事会第八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 宁波永新光学股份有限公司（以下简称"公司"）于 2024 年 4 月 15 日以电 子邮件及专人送达方式发出了关于召开公司第八届董事会第八次会议的通知，本 次会议于 2024 年 4 月 25 日以现场方式召开。本次会议应出席董事 9 名，实际出 席董事 9 名，公司监事及高级管理人员列席会议，会议由联席董事长毛磊先生主 持。本次会议的召开符合《公司法》和《公司章程》的有关规定，所作决议合法 有效。 证券代码：603297 证券简称：永新光学 公告编号：2024-013 宁波永新光学股份有限公司 二、董事会会议审议情况 经过充分讨论，会议审议并通过了如下决议： 1、审议并通过《2023 年度董事会工作报告》 表决结果：同意 9 票；反对 0 票；弃权 0 票。 本议案尚需提交公司股东大会审议。 2、审议并通过《2023 年度独立董事述职报告》 公司独立董事向董事会递交了《2023 年度独立董事述职报告》，并将在公司 2023 ...

证券代码：603297 证券简称：永新光学 公告编号：2024-025 宁波永新光学股份有限公司 （一）委托理财目的 为充分利用公司闲置自有资金，提高公司资金使用效率，在不影响公司日常 经营活动的情况下，增加公司资金收益，为公司及股东谋取更多的投资回报。 （二）资金来源 本次委托理财资金为公司闲置自有资金。 关于使用闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 委托理财期限：第八届董事会第八次会议审议通过之日起 12 个月，在该 额度范围和期限内，资金可以循环滚动使用，期满后归还至公司自有资金账户。 履行的审议程序：第八届董事会第八次会议、第八届监事会第七次会议 一、本次使用闲置自有资金进行现金管理的概况 （三）委托理财方式 在不影响正常生产经营、保障资金安全且风险可控的前提下，用于购买安全 性高、流动性好的现金管理产品。 （四）委托理财额度 委托理财受托方：商业银行等具有合法经营资格的金融机构 委托理财金额：最高不超过人民币 70,000.00 万元的闲置自有资金 委托理财产 ...

证券代码：603297 证券简称：永新光学 公告编号：2024-016 宁波永新光学股份有限公司 关于 2023 年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）和 上海证券交易所印发的《上海证券交易所上市公司自律监管指引第 1 号——规范 运作（2023 年 12 月修订）》（上证发〔2023〕193 号）及相关格式指引的规定， 将宁波永新光学股份有限公司（以下简称"公司"）2023 年度募集资金存放与 使用情况专项说明如下。 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可〔2018〕1253 号文核准，并经上海证 券交易所同意，本公司由主承销商海通证券股份有限公司采用向社会公众公开发 行方式，向社会公众公开发行人民币普通股（A 股）股票 2,100 万股，发行价为 每股人民币 25.87 ...

证券代码：603297 证券简称：永新光学 公告编号：2024-023 宁波永新光学股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次会计政策变更前，公司执行财政部颁布的《企业会计准则——基本准则》 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释以及其他相关 规定。 （四）本次变更后采用的会计政策 重要内容提示： 宁波永新光学股份有限公司（以下简称"公司"）根据中华人民共和国财政 部（以下简称"财政部"）颁布的《关于印发<企业会计准则解释第17号>的通知》 （财会[2023]21号，以下简称"解释第17号"）的要求变更相应的会计政策，本 次会计政策变更无需提交股东大会审议，相关会计政策变更的具体情况如下： 一、本次会计政策变更概述 （一）本次会计政策变更的原因 2023年10月25日，财政部发布了解释第17号，规定了"关于流动负债与非流 动负债的划分"、"关于供应商融资安排的披露"及"关于售后租回交易的会计 处理"。同时，解释第17号要求：关于"关于流动负债与非流动负债的划分 ...

宁波永新光学股份有限公司 2023 年度独立董事述职报告 作为宁波永新光学股份有限公司（以下简称"公司"）的独立董事，在 2023 年度的工作中，本人按照《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司治理准则》 《上市公司独立董事管理办法》等法律法规、规范性文件以及《公司章程》、公 司《独立董事工作制度》的规定和要求，充分履行诚信与勤勉的义务，认真履职， 促进公司规范运作，切实维护公司整体利益和全体股东的合法权益。现将 2023 年度履职情况报告如下： 一、本人基本情况 闫国庆，男，1960 年出生，中国国籍，无永久境外居留权，博士学历。曾任 沈阳市外经贸委国际经济贸易研究所副所长、沈阳市辽中县人民政府副县长、浙 江万里学院副校长兼商学院院长、宁波海上丝绸之路研究院院长；现任宁波海上 丝绸之路研究院首席专家、三江购物俱乐部股份有限公司独立董事、贝发集团股 份有限公司独立董事、宁波艾克姆新材料股份有限公司独立董事、荣安地产股份 有限公司独立董事、宁波舟山港股份有限公司独立董事。于 2021 年 9 月 10 日至 2024 年 4 月 1 日 ...

宁波永新光学股份有限公司 关于2024年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2024年度日常关联交易预计无需提交公司股东大会审议。 证券代码：603297 证券简称：永新光学 公告编号：2024-017 本次公司预计 2024 年度日常关联交易金额为 1,695.00 万元，未超过公司最 近一期经审计净资产绝对值的 5%，因此无需提交公司股东大会审议。 （二）2023年度日常关联交易的预计和执行情况 本次预计关联交易为公司正常生产经营行为，以市场价格为定价标准，关 联交易基于自愿平等原则且价格公允，不会损害公司和股东、特别是中小股东的 利益，不会影响公司的正常生产经营，没有对公司独立性构成影响。 一、2024 年度日常关联交易预计基本情况 （一）日常关联交易履行的审议程序 2024年4月25日，宁波永新光学股份有限公司（以下简称"公司"）召开了第 八届董事会第八次会议和第八届监事会第七次会议，分别审议通过了《关于2024 年度日常关联交易预计的议案》，公司预计2024年度日 ...

Financial Performance - Revenue for 2023 reached 854.13 million RMB, a 3.02% increase compared to 2022[8] - Net profit attributable to shareholders decreased by 15.64% to 235.35 million RMB in 2023[8] - Revenue for the reporting period was RMB 854,125,434.83, a 3.02% increase year-over-year[99] - Basic earnings per share (EPS) for 2023 decreased by 15.75% to RMB 2.14 compared to RMB 2.54 in 2022[165] - Diluted EPS for 2023 decreased by 15.42% to RMB 2.14 compared to RMB 2.53 in 2022[165] - Weighted average return on equity (ROE) decreased by 4.33 percentage points to 13.59% in 2023[165] - Revenue and operating net profit both achieved double-digit growth in Q1 2024, with non-GAAP net profit increasing by 27.09% year-over-year[189] - The company's non-recurring profit and loss items totaled RMB 73,506,327.78 in 2023, a significant increase from RMB 62,514,939.23 in 2022[181] R&D and Innovation - R&D investment continues to increase, driving technological innovation and product development[25] - The company's R&D expenses increased due to intensified investment in research and development during the reporting period[75] - R&D expenses increased by 15.58% to RMB 91,762,758.69 compared to the previous year[99] - The company has 340 R&D personnel, accounting for 24.51% of the total workforce[82] - The company is leading the "Ultra-High Resolution Live Cell Imaging Microscope Research and Application" project under the national "14th Five-Year Plan" major scientific instrument initiative[39] - The company established partnerships with Zhejiang University and the Chinese Academy of Sciences, focusing on advanced technologies such as super-resolution microscopy and AI algorithms[197] - The company acknowledges the need for continuous technological innovation and new product development to maintain its competitive edge[138] Market Expansion and International Operations - The company is accelerating overseas market expansion, focusing on emerging and high-end markets[18] - The company has expanded its market presence in India, South Korea, and other international markets, leveraging developed markets as benchmarks for rapid expansion[68] - Overseas assets amount to RMB 50,232,131.45, representing 2.40% of total assets[87] - Export revenue accounted for 46.65% of total revenue, with USD as the primary settlement currency for overseas clients[120] - The company's overseas market share for high-end microscopes increased significantly in 2023, with market teams visiting Europe, Japan, and Singapore[190] - The company is enhancing its international market coordination and overseas marketing capabilities to secure high-quality projects and manage risks effectively[139] - The company faces challenges in international operations due to geopolitical tensions and regional conflicts, which may impact its global brand influence[139] - The company is actively monitoring and managing risks related to its international operations and market environment[139] Product Development and Business Growth - The company has developed multiple high-end medical optical components, including endoscope lenses, surgical mirrors, and detection objectives, contributing to the localization of high-end medical devices[44] - The company's medical optical products, including embedded microscopy systems and digital slide scanners, are gaining traction in markets such as gene sequencing, cancer screening, and gynecological disease detection[53] - The company's medical optics business has grown by over 50% in the past two years, covering more than 70% of key players in the domestic laparoscopic system market[186] - The company's medical optics business revenue reached 63 million RMB in 2023, exceeding the target set in the equity incentive plan[194] - The company successfully developed a 3D 4K fluorescence module for endoscopes and gained customer recognition[194] - The company's barcode scanning business saw sequential growth in each quarter since Q3 2023, with orders from Zebra and Honeywell expected to start mass production in H2 2024[193] - The NSR950 super-resolution microscope achieved its first sale, marking the company's world-class technical level in optical microscopy[192] - The company's NCF series of confocal microscopes now covers products priced between 800,000 RMB and 1.5 million RMB, forming a complete product family[191] - The company's NIB1000 inverted biological microscope began mass sales, with technical indicators ranking among the global advanced level[192] - The high-end microscope brand NEXCOPE series revenue grew from 4 million RMB in 2018 to nearly 140 million RMB in 2023, with a compound annual growth rate exceeding 100%[190] Strategic Partnerships and Industry Leadership - The company has established long-term strategic partnerships with industry leaders such as ZEISS, Leica, Zebra, Honeywell, and Cognex, enhancing its R&D and manufacturing capabilities[45] - The company has led the formulation of 1 international standard and participated in the revision of 108 national and industry standards, along with 3 group standards, establishing itself as a leader in industry standards[55] - The company was nominated for the 5th "China Quality Award" and the 9th "Zhejiang Provincial Government Quality Award," reflecting high recognition from the government and industry[188] - The company has been recognized with the "China Quality Award Nomination" for its contributions to high-precision, automated, and intelligent microscopy development[59] Operational Efficiency and Management - The company invested over 50 million yuan in information technology and automation equipment in 2023, integrating systems like SAP, CRM, PLM, E-HR, MES, WMS, and ESB to enhance management efficiency[27] - The company has established a comprehensive management system, including ISO9001, ISO14001, ISO13485, and IATF16949 certifications, ensuring high-quality production and compliance[72] - The company has implemented a "8090 Plan" to promote younger management teams, with 80s and 90s generations forming the core of middle and senior management, enhancing resource allocation and solution formulation[57] - The company is strengthening its sales, supply chain, and manufacturing processes through informatization to improve output scale and overall operational efficiency[135] - The company is investing in the construction of new factories to support its growth and operational efficiency[136] Cost and Profit Analysis - Gross margin remained stable at around 40% due to deep collaborations with industry leaders like Zeiss and Leica[13] - Non-recurring gains in 2023 included 60.40 million RMB from non-current asset disposals and 33.45 million RMB from government subsidies[10] - Non-current asset disposal gains amounted to RMB 50,216,584.00, contributing 19.94% to total profit[110] - Government subsidies received during the reporting period totaled RMB 33,453,813.29, accounting for 13.29% of total profit[110] - The company's total cost for optical components and microscope series increased by 9.51% year-over-year, with significant increases in raw material costs for microscope series (14.08%) and direct labor costs (39.66%)[79] - Production volume of optical components decreased by 22.55% to 25,181,004 units, while sales volume decreased by 24.75% to 29,323,798 units[102] Future Plans and Strategic Goals - The company completed its IPO fundraising projects, including the LiDAR components project, by January 2024[7] - The "Medical Optical Equipment and Precision Optical Components Production Base" project is expected to complete main structure acceptance and partial decoration by 2024[16] - The company is preparing for potential demand growth following the Chinese government's policy on equipment updates and consumer upgrades in 2024[21] - The company aims to become a globally renowned optical enterprise by 2035, establishing a high-quality image for Chinese scientific instruments worldwide[95] - The company focuses on a "2+2" business layout, emphasizing optical microscopes and barcode machine vision as core businesses, while expanding into emerging sectors like LiDAR and medical optics[135] - The company plans to distribute a cash dividend of RMB 9.55 per 10 shares, totaling RMB 106,167,827.50, representing 45.11% of the net profit attributable to shareholders in 2023[156] - The company's total share capital as of April 25, 2024, is 111,170,500 shares[156] Industry and Market Trends - The global barcode scanner market was valued at $6.94 billion in 2021 and is projected to reach $10.77 billion by 2027, with a CAGR of 7.6%[34] - The company has secured a significant position in the global barcode optical components market, becoming the largest global supplier and expanding into chip packaging and modular product development[71] - The company's optical components business, including barcode machine vision, laser radar, and medical optics, operates on a direct sales model with high customer stickiness and market competitiveness[67] - The company is exposed to risks from macroeconomic slowdown and market fluctuations, which could lead to decreased demand and affect new business development[140]